Gix Internet Ltd. (GIXI) has initiated a process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE). The last TASE trading day is expected to be January 25, 2027, with delisting expected on or about January 27, 2027. Shareholders may trade on the TASE through market close on the final trading day.
The shares will continue to trade on the Nasdaq Capital Market under GIXI, and TASE-traded shares may be transferred to Nasdaq under applicable procedures. The company will continue filing public reports and disclosures with the SEC and Nasdaq. Its board approved the transition to exclusive Nasdaq trading, with the stated objective of potentially enhancing Nasdaq liquidity and focusing investor and public-relations efforts on U.S. capital markets.
Gix Internet Ltd. (GIXI) reported two milestones announced by Quantum X Labs, in which Gix holds approximately 13% (2,818,585 shares). On Google’s public hardware data, QXL reported its decoder produced 12.7% fewer logical errors than PyMatching at code distance 3 and 12.1% fewer at distance 5. In a separate streaming evaluation, its observed logical error rate was approximately 6% lower at distance 3 and 9% lower at distance 5.
QXL also reported that LayerQake reduced measurement bias from approximately 11% to 15% to below 6% on each of three IBM quantum processors, and reduced maximum cumulative error 15- to 21-fold, meeting its two predefined success criteria. Gix said it does not control QXL, had not independently verified the results, and cannot assure QXL’s progress will benefit Gix or its shareholders.
Gix Internet Ltd. reports Chief Executive Officer Amir Nardimon directly held 86,479 ordinary shares as of August 31, 2026. This excludes up to 89,624 additional shares he may become entitled to receive for no additional consideration upon achievement of predetermined milestones.
He also directly held options to purchase 44,608 and 46,311 ordinary shares, each at a $6.31 exercise price, expiring July 12, 2035, and July 11, 2036, respectively. The price is presented in USD using the Bank of Israel exchange rate reported October 16, 2026.
Gix Internet Ltd. (GIXI) adopted, effective October 18, 2026, the corporate-governance exemption under Regulation 5D of Israel’s relief regulations for public companies listed outside Israel. The company states it has no controlling shareholder and meets the exemption’s conditions. It will follow Nasdaq Listing Rules for a majority-independent board and the composition of its audit and compensation committees instead of the corresponding Israeli Companies Law requirements.
As of October 18, 2026, Ron Silberman and Shoshi Eizenberg Hertz, previously classified as external directors, are no longer classified that way under the Companies Law. Under the transition rules, they may choose to remain directors until the earlier of the end of their original terms or the second annual shareholder meeting after adoption.
Gix Internet Ltd. Chief Financial Officer Amihay Hadad reported direct ownership of 11,082 ordinary shares, plus two options to purchase ordinary shares: one covering 10,000 underlying shares at a $48.80 exercise price and expiring February 2, 2029, and one covering 3,333 underlying shares at a $34.16 exercise price and expiring June 22, 2030. The option exercise prices are presented in U.S. dollars after conversion from NIS using the Bank of Israel rate reported October 7, 2026, of NIS 3.0740 per U.S. dollar.
Gix Internet Ltd. (symbol: GIXI) is the issuer of record for a Form 3 filing submitted to the SEC. Director Yoresh Eliyahu reported direct holdings of 12,116 ordinary shares and warrants covering 10,020 ordinary shares as of August 31, 2026. The warrants have a listed exercise price of $6.83 and expire on August 13, 2028.
Gix Internet Ltd. director Carmel Liron reported direct ownership of options to purchase 3,333 ordinary shares. The option is listed with an exercise date of September 14, 2022, and an expiration date of September 13, 2032. Its exercise price was originally NIS 51.9 and is presented as $16.88 using the Bank of Israel exchange rate reported October 7, 2026: NIS 3.0740 = USD 1.00.
Gix Internet Ltd. announced that autonomous robots operated by its subsidiary deliverz.ai have begun delivering blood and bone marrow at Sheba Medical Center, expanding an ongoing project for chemotherapy medication deliveries. Bone marrow specimens move from hematology to the laboratory, while donated blood moves from the donation center to the blood bank.
deliverz.ai’s platform coordinates autonomous robots and human resources across hospital logistics workflows. The deployment has completed thousands of delivery missions in indoor and outdoor environments, and further expansion is planned for additional medication and diagnostic-specimen transport workflows.
Gix Internet Ltd. (GIXI) announced a $500,000 strategic investment in U.S.-based Physical AI robotics company Ottonomy, Inc. through a simple agreement for future equity (SAFE). The SAFE gives Gix contractual rights to receive Ottonomy equity upon certain qualifying financing or other specified future events.
The investment advances Gix’s strategy to build one intelligent management and orchestration layer for robots, people and autonomous systems, leveraging its Deliverz.ai platform and Ottonomy’s L4 autonomous robotic systems. On August 4, 2026, the companies also signed a non-binding letter of intent contemplating potential additional investments that could lead to Gix first obtaining a strategic stake and potentially a majority interest in Ottonomy, subject to due diligence, financing, definitive agreements and approvals. The SAFE investment is expected to close during the week of September 16, 2026, subject to customary closing conditions.
Gix Internet Ltd. (GIXI) filed a report highlighting the launch of its new corporate website, which showcases its strategy to build one intelligent, AI-powered management and orchestration layer coordinating robots, people and autonomous systems, with an initial commercial focus on hospital logistics through its wholly owned subsidiary Deliverz.ai.
Deliverz.ai’s platform is in continuous commercial use at Sheba Medical Center since December 2025, where it has completed more than 7,000 autonomous missions and reduced chemotherapy delivery times between the pharmacy and treatment units from 40 minutes to 14 minutes, under a public tender that allows for potential deployment of up to 30 robots. The company is introducing this approach to U.S. healthcare organizations and holds two granted physical-AI navigation patents registered in Israel, Europe and Korea, with additional applications under review in the United States and Japan.